ClinicalTrials.gg
RecruitingNCT06031025FUSIDUpdated Mar 11, 2025

Prevalence and Natural History of Functional Gastrointestinal Disorders Among At-risk Infants.

An observational study in Functional Gastrointestinal Disorders, Gastroesophageal Reflux and Constipation - Functional, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to participants aged 3 Months to 24 Months. Per ClinicalTrials.gov, last updated 2025-03-11.

Primary conditionGastroesophageal RefluxRegistry: Gastrointestinal DiseasesReclassifiedWhy we changed it
Registry
Gastrointestinal Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Gastroesophageal Reflux
Why
  1. The study's listed conditions name Gastroesophageal Reflux, a narrower term within Gastrointestinal Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started May 2022; still recruiting 4 years 5 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
71
Ages
3 Months to 24 Months
Sex
All
01

Study summary

The goal of this observational study is to learn about the prevalence and characteristics of functional gastrointestinal disorders (FGID) in at risk infants (former preterm infants and those with birth asphyxia) during the first 2 years of life. The main questions it aims to answer are:

  • evaluate the prevalence of symptoms related to gastro-esophageal reflux (GER), of functional gastrointestinal disorders during the first 2 years of life
  • describe growth parameters during follow-up up to the corrected age of 2 years Participants will be assessed clinically and with a structured questionnaire based on the Rome IV criteria to describe FGID.
Read the detailed description

Infants will undergo clinical assessment at 3, 6, 12, 24 months' corrected age at the local Follow-up clinic.

Clinical examination, anthropometric measurement and data from a structured questionnaire to detect FGID will be performed.

Z-scores for weight, length and head circumference will be calculated according to the World Health Organization (WHO) standards.

Data from the questionnaires will be collected. Clinical characteristics of patients and perinatal data will be collected and analyzed by appropriate statistical methods.

The prevalence and characteristics of FGID in the study population will be compared to published data (mostly from term infants).

02

Conditions studied

  • Functional Gastrointestinal Disorders
  • Gastroesophageal Reflux
  • Constipation - Functional
  • Diarrhea
  • Dyschezia
  • Colic, Infantile
  • Vomiting; Cyclical
03

In context

Gastroesophageal Reflux Reclassified

1,211 studies on the registry are indexed under Gastroesophageal Reflux; 202 are open to participants now.

This study's planned enrollment of 71 is below the median of 178 across 348 observational studies indexed under Gastroesophageal Reflux.

Browse Gastroesophageal Reflux studies →

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 952 studies on the registry; 541 are open to participants now.

Compared within Gastroesophageal Reflux, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Gastrointestinal Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
3 Months to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Infants matching the inclusion criteria will be enrolled in the local Follow-up program (as per clinical routine of the local Institution).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • infants with gestational age at birth \< 31 weeks
  • infants with gestational age at birth \< 37 weeks and major respiratory or neurologic morbidity
  • infants with history of perinatal asphyxia

Exclusion criteria

Exclusion Criteria:

  • lack of
  • diagnosis of congenital or other major gastrointestinal disease (i.e. inflammatory bowel disease, cancer)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
71 participants (estimated)
Patient registry
No

Interventions

  • OtherQuestionnaire, clinical examination

    At each follow up visit, a clinical examination and anthropometric evaluation will be performed. Parents will fill a structured questionnaire to describe the occurrence and characteristics of functional gastrointestinal disorders.

06

What researchers measure

Primary outcomes

  1. Prevalence of FGID

    Occurrence of FGID (percentage of patients)

    Time frame: 3, 6, 12, 24 months of corrected age

  2. Frequency of FGID

    Frequency of FGID (i.e. number of symptoms per day)

    Time frame: 3, 6, 12, 24 months of corrected age

  3. Severity of FGID

    Severity (scales from 0 to 10 for increasing values) of FGID

    Time frame: 3, 6, 12, 24 months of corrected age

Secondary outcomes

  1. Somatic growth: weight

    Measurement of weight and calculation of z-scores based on reference standards by the World Health Organization

    Time frame: 3, 6, 12, 24 months of corrected age

  2. Somatic growth: head circumference

    Measurement of head circumference and calculation of z-scores based on reference standards by the World Health Organization

    Time frame: 3, 6, 12, 24 months of corrected age

  3. Somatic growth: length

    Measurement of length and calculation of z-scores based on reference standards by the World Health Organization

    Time frame: 3, 6, 12, 24 months of corrected age

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Steutel NF, Zeevenhooven J, Scarpato E, Vandenplas Y, Tabbers MM, Staiano A, Benninga MA. Prevalence of Functional Gastrointestinal Disorders in European Infants and Toddlers. J Pediatr. 2020 Jun;221:107-114. doi: 10.1016/j.jpeds.2020.02.076. PubMed 32446468 ↗
  • Robin SG, Keller C, Zwiener R, Hyman PE, Nurko S, Saps M, Di Lorenzo C, Shulman RJ, Hyams JS, Palsson O, van Tilburg MAL. Prevalence of Pediatric Functional Gastrointestinal Disorders Utilizing the Rome IV Criteria. J Pediatr. 2018 Apr;195:134-139. doi: 10.1016/j.jpeds.2017.12.012. Epub 2018 Feb 3. PubMed 29398057 ↗
  • Benninga MA, Faure C, Hyman PE, St James Roberts I, Schechter NL, Nurko S. Childhood Functional Gastrointestinal Disorders: Neonate/Toddler. Gastroenterology. 2016 Feb 15:S0016-5085(16)00182-7. doi: 10.1053/j.gastro.2016.02.016. Online ahead of print. PubMed 27144631 ↗
  • Iacono G, Merolla R, D'Amico D, Bonci E, Cavataio F, Di Prima L, Scalici C, Indinnimeo L, Averna MR, Carroccio A; Paediatric Study Group on Gastrointestinal Symptoms in Infancy. Gastrointestinal symptoms in infancy: a population-based prospective study. Dig Liver Dis. 2005 Jun;37(6):432-8. doi: 10.1016/j.dld.2005.01.009. Epub 2005 Mar 2. PubMed 15893282 ↗
  • Scarpato E, Salvatore S, Romano C, Bruzzese D, Ferrara D, Inferrera R, Zeevenhooven J, Steutel NF, Benninga MA, Staiano A. Prevalence and Risk Factors of Functional Gastrointestinal Disorders: A Cross-Sectional Study in Italian Infants and Young Children. J Pediatr Gastroenterol Nutr. 2023 Feb 1;76(2):e27-e35. doi: 10.1097/MPG.0000000000003653. Epub 2022 Nov 1. PubMed 36705695 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06031025
Responsible party
Sponsor
First posted
Sep 11, 2023
Start date
May 20, 2022
Primary completion
Sep 30, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Mar 11, 2025

Study contacts

Stefano Nobile, MD, PhD, MSc
Contact
stefano.nobile@policlinicogemelli.it
+390630156937
Stefano Nobile, MD, PhD, MSc
principal investigator · Fondazione Policlinico Universitario A. Gemelli, IRCCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion